Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin deletion in Sost KO mice (Sost À/À ) causes high bone mass (HBM) similar to sclerosteosis patients. Sost À/À mice have been shown to display an up to 300% increase in bone volume/total volume (BV/TV), relative to age-matched controls. It has been postulated that the main source of skeletal sclerostin is the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost À/À mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (Sost iCOIN/iCOIN ) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) midstage osteoblasts and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the amplitude of the HBM phenotype in the appendicular skeleton and the B-cell defect described in the global KO. Despite WT expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these mice also had a significant increase in bone mass in the vertebrae, but the sclerostin released in circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both Col1 and Dmp1 deletion resulted in a similar 80% significant increase in trabecular bone mass, but only Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several cell types within the Prx1-osteoprogenitor-derived lineages contribute significant amounts of sclerostin protein to the paracrine pool of Sost in bone.
Introduction

S
clerostin (Sost) is a secreted Wnt antagonist that primarily functions to negatively regulate bone formation by preventing the propagation of Wnt signaling through the low-density lipoprotein receptor-related proteins (LRP4/5/6 Wnt coreceptors) in osteoblasts, preosteocytes, and osteocytes. (1, 2) Patients carrying homozygous SOST null mutations (sclerosteosis) display generalized high bone mass (HBM), (3, 4) a phenotype that is recapitulated in Sost KO mice (Sost À/À ). (5, 6) Conversely, overexpression of SOST in transgenic mice (SOST tg ) results in osteopenia. (7) Shortly after the gene responsible for sclerosteosis was cloned, SOST transcripts were reported in bone, BM, cartilage, kidney, liver, lung, heart, and pancreas (3, 4) ; however, histological examination determined that the osteocytes within cortical and trabecular bone were a dominant source of sclerostin. (8, 9) These observations support the hypothesis that the HBM phenotype in both patients and mice is based on a sclerostin deficiency in osteocytes, and that sclerostin acts in a paracrine manner. (10) 1 postmenopausal women compared with premenopausal women. (11, 12) Estrogen treatment administered to postmenopausal women significantly decreased serum sclerostin and mRNA levels in bone biopsies compared with untreated postmenopausal women, (11) (12) (13) suggesting that estrogen may function to inhibit Sost expression/production. (12, 14) Similarly, an increase in SOST serum levels was documented for aging men and women. (12) Sclerostin serum levels are affected by age, sex, hormone, and disease status, suggesting that sclerostin serum levels could impact bone physiology. Osteocytes are the likely source of most of the circulating sclerostin found in serum. Thus, all of the above-mentioned sclerostin-modulating factors could control sclerostin transcriptionally or posttranscriptionally in bone. Another unresolved issue is whether bone-associated cell types other than osteocytes also contribute to the sclerostin protein pool locally and systemically, including osteoblasts, osteoclasts, bone-lining cells, mesenchymal stem cells, or other progenitors along the osteoblastic-and chondrogenic-lineages. To understand the cell-type specific contributions to the HBM phenotype described in Sost À/À mice and to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (Sost iCOIN/iCOIN ) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre-driven recombination), which targets osteoprogenitors and their progeny; (2) midstage osteoblasts and their progenitors (Col2.3-Cre-driven recombination); (3) early-stage osteocytes (Dmp1-Cre-driven recombination); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre).
We were particularly interested in determining whether any of these mice phenocopy the global Sost deletion. Here we show that conditional deletion of Sost in Prx1-expressing cells recapitulates the global high-bone-mass phenotype of Sost À/ À , resulting in $250% more bone in the femur. In contrast, both Col1-a n dDmp1-specific deletions of Sost induced a significant, but milder increase in bone formation, only 30% that of Sost À/À ,o r$80% more bone than WT controls. The vertebrae of Prx1-Cre-deleted Sost mice also displayed a significant 50% increase in bone mass, suggesting that limbbone-derived sclerostin contributes significantly to the serum pool of sclerostin that normally suppresses bone formation in the spine. Moreover, the sclerostin produced in the axial skeleton (ie, in the skeletal tissues that avoid Prx1-Cremediated recombination) is too dilute in the circulation to impair bone formation rates in the appendicular skeleton, where the Sost gene is recombined.
In addition, the relationships and interactions between the diverse cell types within the bone and their reciprocal effects on each other's cell fate decisions have become a focus of intense research, with clinical applications to improve bone fracture healing, prevent age-related bone loss and immune deficiencies. A significant knowledge gap exists as to the contribution of different osteolineage cells to the differentiation, proliferation, and long-term survival of B lymphocytes in the BM. In global sclerostin KO (Sost À/À ) mice, we previously uncovered a cellextrinsic requirement for sclerostin on B-lymphocyte development. (15) Similar to mice with global Sost deletion, the total BM cellularity in the femurs and tibiae was significantly reduced when Sost was deleted from Prx1-expressing cells. However, Blymphocyte development was differentially affected by Sost deletion in the Prx1-, Col1-, and Dmp1-expressing cells, suggesting that a specific population of sclerostin-expressing cells in the bone influences B-cell development and function.
Materials and Methods
Experimental animals
Mice with C57Bl/6 background were used in this study. Sost conditional KO (Sost iCOIN/iCOIN ) mice were generated by inserting an inverted GFP cassette, flanked by lox66 and lox71 sequences, in the intron of the Sost gene as previously described. (16) 
Immunofluorescent staining
Femur and lumbar vertebrae were collected at 16 weeks of age; they were fixed, dehydrated, embedded, and sectioned as previously described. (5) For IF, trypsin/EDTA was used for antigen retrieval for 25 min at 37°C. Primary antibodies: anti-SOST (R&D, AF1589), anti-GFP (Abcam,Cambridge, MA, USA; ab13970), and anti-activated b-catenin (Millipore, Billerica, MA, USA) were used and incubated overnight at room temperature as previously described. (17) Negative control slides were incubated with secondary antibody only. Stained slides were mounted with Prolong Gold with 4,6-diamidino-2-phenylindole (DAPI; Molecular Probes, Eugene, OR, USA). ImagePro Plus V7.0 software (Media Cybernetics, Rockville, MD, USA) and a QIClick CCD camera (QImaging, Surrey, BC, Canada) were used for imaging and photo editing.
Micro-computed tomography
Fourth lumbar vertebrae and whole femora were collected and fixed for 48 hours in 10% neutral buffered formalin, then stored in 70% ethanol at 4°C until scanning. The entire vertebra and the distal 60% of the femur were scanned on a Scanco mCT-35 specimen scanner (Scanco Medical AG, Br€ uttisellen, Switzerland) using 60 kVp, 180 mA, 750-ms integration time, and 10-mm voxel size. (18) The entire cancellous region of the lumbar vertebra within 100 um of the endplates was isolated by manual analysis and included in the analysis. For the distal femur metaphysis, a 2-mm region of secondary spongiosa was isolated by manual analysis. The region of interest began 1-mm proximal to the distal growth plate and extended proximally for 2 mm. Prior to scanning, the total length of each femur was measured with digital calipers; these measurements were used to identify the mid-diaphysis slice in each femur CT scan by taking into account slice thickness (10 mm) and counting up in slices from the distal tip of the condyles until the calculated midshaft was reached. The central 20 slices at midshaft were analyzed for cortical properties.
Western blot and ELISA Femur and lumbar vertebrae were collected from 12-to 16-week-old age-matched mice, frozen in liquid nitrogen, and 2 YEE ET AL. stored at À80°C until extraction. The bones were homogenized in 500 mL of radioimmunoprecipitation assay buffer with an appropriate volume of protease inhibitor cocktail (SigmaAldrich, St. Louis, MO, USA) at 1 mL/20g tissue, then incubated on ice for 20 min prior to centrifugation at 18,000g for 20 min at 4°C. The protein lysate supernatant was then quantified using BCA assay (Pierce, Rockford, IL, USA) and stored at À80°C. SDS-PAGE was performed with equal quantities of total protein per sample on NuPAGE protein gels (Thermo Fisher Scientific, Rockford, IL, USA). Protein was then blotted onto a PVDF membrane (LI-COR Biosciences, Lincoln, NE, USA) for Western blot analysis. Membranes were probed with primary antibodies specific for Sost (AF1589; R&D Systems, Minneapolis, MN, USA) and b-actin (926-42210, LI-COR Biosciences) followed by IRDye 800CW donkey anti-goat and IRDye 680RD donkey anti-rabbit secondary antibodies (LI-COR Biosciences). Membranes were then imaged using an Odyssey FC imaging system (LI-COR Biosciences). Mouse sclerostin (41-SCLMS-EO1; ALPCO, Salem, NH, USA), Rankl (R&D Systems Cat#MTR00), and Ctx-1 ELISA kits (RatLaps EIA CTX-1 Cat# AC-06F1; Immunodiagnostics, Fountain Hills, AZ) were used according to the manufacturer's instructions (1:10 dilution for sclerostin and 1:1 dilution for Rankl and Ctx-1) to measure serum levels as previously described (N ¼ 3 to 4 per group). (19) Bone marrow harvests Mice were euthanized by CO 2 inhalation followed by cervical dislocation. Whole legs were dissected and muscles were removed. Bones were crushed with a mortar and pestle in medium 199 containing 2% fetal calf serum (M199þ) to release the BM. BM cells were rinsed away from the bone chips with PBS and collected into 15-mL conical tubes, resuspended by trituration and filtered through 70-m nylon mesh squares into sterile tubes. Cells were next washed with M199þ and centrifuged at 1500 rpm at 4°C for 5 min, after which cell pellets were resuspended and treated with ACK lysis buffer to remove erythrocytes. The ACK-treated cells were washed and resuspended in M199þ; total cell counts were obtained using a hemocytometer and trypan blue staining to exclude dead cells.
Analysis of hematopoietic cell lineages by flow cytometry
The following antibodies were purchased from eBioscience (Santa Clara, CA, USA) or Biolegend (San Diego, CA, USA):
, and IgD-(11-26c.2a-) BV510. Per sample, 1 to 2 Â10 6 cells were stained in 96-well V-bottom plates (Nunc, Inc., Rochester, NY, USA) with their designated antibody cocktail and incubated for at least 15 min at 4°C before washing with FACS buffer and centrifuging at 2000 rpm at 4°C for 3 min. Supernatants were removed from the plates and cells incubated with streptavidin-Pacific blue to develop biotinylated CD11b-stained cells when required. Cell viability was assessed using DAPI or propidium iodide (PI) solution at a final concentration of 0.2 mg/mL. Cells were acquired on a Becton Dickinson LSR II (Becton Dickinson, Franklin Lakes, NJ, USA) and flow cytometric analysis was performed using FlowJo software (FlowJo, LLC, Ashland, OR, USA).
Statistics
All data were expressed as the mean AE SD. For mCT and flow cytometry results, statistical analysis was done using a Student's t test with a two-tailed distribution, with two-sample equal variance (homoscedastic test) and one-way ANOVA with multiple comparisons. For all tests, p < 0.05 was considered statistically significant.
Results
Dmp1-Cre deletion pattern most closely recapitulates endogenous Sost expression in bone Conditional deletion of Sost from different cell populations allows us to determine cell-specific contributions to bone metabolism and to distinguish local from systemic effects. Using a previously described Sost conditional loss-of-function by inversion allele (Sost iCOIN/iCOIN ), (16) we eliminated Sost expression in (1) the limb mesenchyme (Prx1-Cre) (20) ; (2) osteoblasts (Col1-Cre) (21) ; and (3) osteocytes (Dmp1-Cre). (22) Upon Cre-mediated recombination, the conditional Sost allele undergoes premature termination of the endogenous Sost transcript, while simultaneously activating enhanced green fluorescent protein (eGFP) in frame with Sost, allowing us to track endogenous Sost expression using eGFP in cells that are now sclerostindeficient. (16) ; Dmp1-Cre with the endogenous Sost expression in the control Sost iCOIN/iCOIN mice. Cortical bone expression of eGFP was highest in the osteocytes of Dmp1-Cre-deleted mice, and punctate expression was also detected in the matrix, suggesting that the Sost-eGFP fusion protein is able to exit the osteocytes (Fig. 1A-D) . Because eGFP is a membrane-bound version, we speculate that this expression may be due to microvesicles shed by osteocytes. Sost iCOIN/iCOIN ; Col1-Cre-deleted mice displayed the lowest expression levels in cortical osteocytes (Fig. 1C) , suggesting that only a minority of embryonically labeled Col1-positive cell mature into osteocytes. In the trabecular region of the femurs, Dmp1-Cre mice also had the greatest expression; the expression was higher than the endogenous Sost expression (Fig. 1A, D) , suggesting that these cells are accumulating higher levels of Sost-eGFP than in the endogenous bone may be caused by retention of eGFP in the membrane ( Fig. 1E-H ). Similar to the cortical bone results, Sost iCOIN/iCOIN ; Col1-Cre mice also expressed eGFP in fewer trabecular osteocytes (Fig. 1G ). The expression of eGFP in the vertebrae of Sost iCOIN/iCOIN ; Col1-Cre and Sost iCOIN/ iCOIN ; Dmp1-Cre was similar to that described above for the femoral trabeculae; however, consistent with its site of Cre recombinase expression, none of the Sost iCOIN/iCOIN ; Prx1-Cre mice express eGFP in the vertebrae (Fig. 1I-L) . Western blot analysis showed the highest Sost-eGFP and the lowest Sost expression in the Sost iCOIN/iCOIN ; Prx1-Cre femurs (Prx1), whereas no Sost-eGFP was detected in the vertebrae, consistent with the Prx1-Cre site of expression in appendicular skeleton (Fig. 1M ). Sost serum levels were reduced by $50% in Prx1-Cre mice, but no detectable Sost was measured in Dmp1-Cre and Col1-Cre (Fig. 1N ). These data suggest that Sost serum levels in Prx1-Cre mice are exclusively derived from the axial skeleton.
Dmp1-Cre deletion of Sost does not recapitulate Sost
À/À HBM phenotype Originally, Sost was described as an osteocyte specificgene, (23) a n da l t h o u g hi nr e c e n ty e a r sSost expression has been found in other organs and cell types of the skeleton, (8) osteocytes do express a robust amount of sclerostin (Fig. 1A (Fig. 2G ).
Prx1-Cre deletion recapitulates Sost
À/À high bone mass phenotype in the femur To determine whether conditional ablation of Sost in the limb mesenchyme, mature osteoblasts, or osteocytes is sufficient to recapitulate the HBM phenotype observed in the Sost À/À mice, we also bred Sost iCOIN/iCOIN mice to Prx1-Cre, in addition to Col1-Cre and Dmp1-Cre ( Fig. 2A-D) . All conditional KO mice were indistinguishable in size and weight from their same-sex Cre-negative control littermates. At 16 weeks of age, a mCT analysis of distal femurs showed that trabecular bone volume fraction (BV/TV) in all conditional KOs was significantly higher than the Cre-negative controls ( Fig. 2A-E) ; however, only the Sost iCOIN/iCOIN ; Prx1-Cre mice had a BV/TV increase of 257% (Table 1) , a value similar to that of age-matched Sost À/À mice (þ221%; Table 2), whereas both Sost iCOIN/iCOIN ;C o l 1 -C r eand Sost iCOIN/iCOIN ; Dmp1-Cre mice had BV/TV increases of 85% and 81%, respectively ( Fig. 2G ; Table 1 ).
Even though Sost iCOIN/iCOIN ; Prx1-Cre femurs most closely resembled femurs from Sost À/À mice, there were several noted differences. Although Sost À/À did not display a significant increase in trabecular number, with only an 8% increase above WT, Sost iCOIN/iCOIN ; Prx1-Cre femurs had a significant 24.18% increase in trabecular number (Tables, 2 1 ). Another significant difference was in the cortical values, where Sost iCOIN/iCOIN ; Prx1-Cre femurs did not display significant increases in either cortical bone volume, but had a significant increase in cortical thickness; Sost À/À had a significant 69.98% increase in cortical bone volume and a 31% increase in cortical BV/TV (Tables, 2 1 ). Furthermore, neither Sost iCOIN/iCOIN ; Dmp1-Cre nor Sost iCOIN/ iCOIN ;C o l 1 -C r ehad a significant increase in cortical BV/TV despite a significant, but more-modest increase in cortical bone volume (Tables, 2 1 ). Lastly, cortical bone mineral density was unchanged in all conditional Sost mice, whereas Sost À/À mice had a significant 3.21% gain (p value ¼ 0.05) in cortical BMD (Tables, 2 1 ). Consistent with the bone phenotype, levels of b-catenin were highest in the Prx1-Cre cortical and trabecular regions of the femur (Fig. S1 ).
Prx1-Cre deletion results in increased bone formation in the vertebrae
Prx1-Cre drives Cre recombinase expression in uncommitted mesenchymal cells that contribute to bone, cartilage, muscle, and white and brown adipose tissues of the developing appendicular skeleton. Cre is also expressed in portions of the skull, but absent from other parts of the axial skeleton. (20, 24) If Sost is retained locally, we anticipated Prx1-Cre deletion to cause HBM in the appendicular skeleton and to maintain normal bone mass in the axial skeleton, where Sost expression remains unperturbed. Lumbar vertebrae mCT analysis between Sost iCOIN/ iCOIN ; Prx1-Cre and age-matched Sost iCOIN/iCOIN control mice uncovered a significant (55%) increase in the BV/TV ratio, suggesting that a lack of Sost in the appendicular skeleton positively affects bone formation in the vertebrae (Fig. 2aa, F, G ; Table 1 ). Though trabecular number was not different in Sost iCOIN/iCOIN ; Prx1-Cre than in controls, the trabecular thickness was significantly elevated by 16%. In addition, the trabecular bone mineral content was elevated by 88%, half of the Sost À/À value. Interestingly, neither Col1-Cre nor Dmp1-Cre deletion of Sost resulted in BV/TV increases similar to those measured for Sost À/À -displaying an 81% increase and an 88% increase, about half of Sost values (Fig. 2bb, cc, dd, F, G; Tables 1, 2) . 
Distal Femur Trabecular and Cortical Compartments
Prx1-Cre Dmp1-Cre Col1-Cre ; Prx1-Cre mice displayed a significant reduction in total BM cellularity; however, deletion of Sost in osteoblasts and osteocytes had no effect (Fig. 3B) . We further examined the frequency (%) and absolute number of total CD19þ B cells, and observed that the percentage of CD19þ cells was slightly reduced when Sost was deleted in osteoblasts and osteocytes (Fig. 3A, C) , but the absolute numbers of CD19þ cells were significantly reduced in the Sost iCOIN/iCOIN ; Prx1-Cre and Sost iCOIN/iCOIN ; Col1-Cre mice only (Fig. 3D) . The CD19þ B cell population in the BM contains a heterogeneous mixture of B-cell progenitors, developing B cells, and mature B cells, which can be distinguished by expression of B220 and diminishing levels of CD43 (Figs. 4A,S2A) . (24) ) and all committed Bcell stages were observed (15) with changes in both frequency and cell number. Our analysis of the Sost iCOIN/iCOIN ; Prx1-Cre BM showed an increase in the percentage of phenotypically mature B220þ CD43 neg cells compared with no Cre controls (Fig. 4B) . In contrast, the percentage of B220þ CD43 neg cells was significantly decreased in the Sost iCOIN/iCOIN ; Dmp1-Cre BM. This suggested that deletion of Sost in the MSCs resulted in expansion of mature B cells, whereas deletion of Sost in the osteocytes resulted in fewer mature B cells. However, the absolute numbers of B220þ CD43 neg cells were not affected (Fig. S3) . Mature B cells should express high (Figs. 4F,S2B ). In line with this, the Sost iCOIN/iCOIN ; Prx1-Cre mice displayed the lowest proportion of mature IgMþ IgDþ cells among the different mouse strains (Fig. 4F) ; Prx1-Cre BM (Fig. 4E) . These results indicate that deletion of Sost in the Prx1þ cells affects the upregulation of IgM and IgD at the later stages of B-cell maturation.
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We also observed changes in B-cell maturation in the Sost iCOIN/ iCOIN ; Col1-Cre BM, but in contrast to the Prx1-Cre BM, the progenitor and early stages of development were altered. Significantly higher proportions of IgM-IgD-cells were observed at the B220þ CD43 high and B220þ CD43 int stages (Fig. 4C,4D) , as well as a lower proportion IgMþ IgD low cells. This suggests that the progression of B cells from the progenitor to early stages of development was somewhat delayed, and could explain the increased proportion of immature B220þ CD43 low cells in the Sost iCOIN/iCOIN ; Col1-Cre BM (Fig. 4B ) and lower percentage and number of IgMþ IgDþ cells within this subset compared to the other mouse strains (Figs. 4E, S2C,S3C ). Despite these changes, the proportions and numbers of mature B220þ CD43 neg were not similar to Cre controls (Figs. 4F, S3D) . Results from the analysis of B-cell subsets using alternative staining strategies were consistent with these results (data not shown). B-cell development in Sost iCOIN/iCOIN ; Dmp1-Cre BM was not significantly altered at any stage (Fig. 4C-F) . These data suggest that Prx1-Cre and Col1-Cre, but not Dmp1-Cre deletion, remove sclerostin in a subtype of osteoprogenitors required for distinct stages of B-cell development.
ColX-Cre deletion of Sost results in high bone mass
ColX-Cre drives Cre recombinase expression in hypertrophic chondrocytes-cells that recently have been shown to transdifferentiate into osteoblasts. (25, 27) Using lineage tracing, it has been shown that ColX-positive cells substantially participate in trabecular, endosteal, and cortical bone formation. (26) To determine whether conditional ablation of Sost in these cells also affects bone mass, we compared ColX-Cre conditional KOs with the Cre-negative littermates. MicroCT analysis of distal femurs showed that Sost iCOIN/iCOIN ; ColX-Cre KOs had a significant 37.57% increase in the femoral and a 22.71% increase in the vertebral trabecular bone volume fractions (BV/TV) relative to the Cre negative controls (Table 3) . Cortical bone mineral content was slightly elevated, but no other cortical parameters were significantly different, suggesting that ColX-Cre ablates Sost from a unique population of osteoprogenitor cells that give rise to Sost positive cells in adult bone. LacZ staining of mice carrying a Sost-LacZ allele did not detect Sost/LacZ expression in the hypertrophic chondrocytes of neonatal mice (Fig. S4C) , suggesting that the high bone mass phenotype is due to a subpopulation of Sost-deficient osteoblasts and osteocytes, primarily in the trabecular compartment.
Discussion
Sost/sclerostin is highly expressed in the osteocyte population (Fig. S4A, B) ; thus it has been hypothesized that the phenotypes observed in bone and hematopoietic development when Sost is deleted were due to a lack of Sost in the osteocytes. Contrary to this assumption, Dmp1-Cre deletion did not recapitulate the global Sost phenotype, unlike Prx1-Cre, which fully recapitulated the Sost global phenotype in the appendicular skeleton. This result can have several interpretations: Either Dmp1-Cre is incapable of ablating the Sost allele in all Sost-expressing osteocytes, and the residual nonrecombined osteocytes express sufficient Sost to blunt the otherwise strong phenotype locally, or several distinct populations of cells in the bone express Sost, and all these cells are derived from Prx1-positive progenitors. The interpretation that other cell types in addition to osteocytes are important contributors to the local pool of sclerostin protein in bone is further supported by the observation that the Col1-Cre deletion of Sost also had a HBM phenotype, but significant differences were noted between Col1 and Dmp1 deletions. For example, a significant difference was observed in the femoral cortical thickness, where Dmp1 deletion did not increase the cortical thickness, but both Col1 and Prx1 did, implying that a subpopulation of periosteal osteoblasts do express Sost and these cells could be a population of osteochondral progenitors as previously suggested by Quyang and colleagues. (28) Because only Prx1-Cre deletion of Sost recapitulates the HBM phenotype of Sost global KO, in the appendicular skeleton, we can conclude that the only Sost expression affecting bone mass is derived from descendants of Prx1-positive limb bud progenitors (Fig. 5) . During the embryonic development of Prx1-positive MSCs give rise to muscle, adipocyte, and osteochondral progenitors, which are the predecessors of mature myocytes, adipocytes, chondrocytes, hypertrophic chondrocytes, osteoblasts, and osteocytes. Although endogenous Prx1 is also expressed in the vertebrae and is required for early events of skeletogenesis in multiple lineages, (29) the Prx1-Cre transgene expresses Cre recombinase from a limb enhancer; therefore, the Cre expression is restricted to all limb bud MSC derived cells of the appendicular skeleton. (20) Here we showed that Sost deletion in mature osteoblasts and their descendant (Col1-Cre) or mature osteocytes (Dmp1-Cre) elevate bone mass by 80%, respectively, whereas deletion in hypertrophic chondrocytes and their descendants (ColX-Cre) elevated trabecular bone mass by 37%. Although all these individual alleles do have a significant HBM phenotype, yet, they do not cumulatively sum up to Prx1-Cre or Sost À/À alleles (80% þ 80% þ 37.5% < 250% BV/TV; Tables 1-3) , further strengthening the argument that additional Prx1-derived cells are responsible for Sost expression in bone. The two lineages not represented in our collection of Cre alleles are the myogenic and the adipogenic lineages, which cannot yet be excluded as contributors to both the HBM and the B-cell phenotypes. Mining available microarrays and RNA-seq data sets did not identify significant transcript levels of Sost in other Prx-1-derived cell types; however, future improvements in cell purification methods followed by RNA-seq may identify subpopulations of cell expressing Sost. Sost expression has also been observed in the osteoclasts of aging mice (30) ; although we did not examine the phenotype of osteoclast-specific deletion of Sost, neither global Sost KO nor any of the conditional strains examined showed a significant change in markers of resorption (Fig. S5) .
Herein, we have also presented data that emphasize novel roles for sclerostin in MSCs and OBs, which distinctly impact BM cellularity and B-cell maturation. We conclude that the loss of Sost in mature osteocytes does not play a major role in regulating Bcell development. Loss of Sost expression in Prx1-positive MSCs and their descendants resulted in reduced BM cellularity, whereas
Journal of Bone and Mineral Research DELETION OF Sost IN MSC-DERIVED LINEAGES 9 this process was unaffected by Sost-deficiency in mature osteoblasts (Col1-Cre) and osteocytes (Dmp1-Cre). Furthermore, MSC-specific depletion of Sost caused an accumulation of abnormal B cells with no or low expression of IgM and IgD receptors that otherwise appeared phenotypically mature. The changes observed in the frequencies and the absolute numbers of B-cell subsets did not follow the same patterns. For example, the percentage of progenitors and early, immature, and mature Bcell subsets increased or decreased among the different deleter strains, but their numbers were not significantly different among all groups (Figs. 4B, S3 ). This may stem from the fact that MSCs, osteoblasts, and osteocytes have a progenitor-progeny relationship, and it is likely that the deletion of Sost in each cell type is not synchronized, so some MSCs may progress to the osteoblast stage before Sost deletion occurs and support B-cell development normally. Because total BM cellularity is decreased in the Prx1-Cre mice, one might expect that the cell number in all fractions would be proportionally decreased; however, only numbers of B220þ CD43 int immature cells were significantly reduced when Sost was deleted in MSCs, indicating that immature B cells require normal Sost levels. Our findings are consistent with recent work that demonstrated that MSCs and osteoblasts are important "niche cells" for early B-cell development, with respect to their production of CXCL12. (31, 32) CXCL12 expression is regulated by Wnt signaling in BM stromal cells in vitro. (33) We observed diminished CXCL12 levels in nonhematopoietic cells of the bone and correlated the diminished CXCL12 levels with the reduction in B-cell development in the global Sost À/À mice. (17) Our present results suggest that Sost specifically expressed in MSCs and osteoblasts regulate B-cell development, but further analysis is required to determine if expression of CXCL12 and other Wnt target genes are altered in MSCs and osteoblasts in the Prx1-Cre and Col1-Cre Sost deleters.
Alternatively, it is possible that the B-cell defect is indirect. Recently, we have observed that BM adiposity positively correlates with Sost expression levels, such that a mouse model of type I diabetes mellitus with elevated levels of Sost displayed enhanced BM adiposity and this phenotype was rescued by Sost antibody treatment. (19) Also, a recent report has described sclerostin as a promoter of adipogenic differentiation, (34) suggesting that the lack of Sost may impair adipogenesis. BM adipocytes can be lineage-traced using Prx1-Cre and Osx-Cre,in contrast to other adipocyte lineages, (35) and the microenvironment in the BM of aged mice appears to favor adipogenesis over osteogenesis in mesenchymal progenitor cells. (36) The relationship between adipocytes and immune cell development is a current area of research. The transition of human common lymphocyte progenitors to the early Pro-B/Pre-B cell stages have been shown to be inhibited by a soluble factor produced by BM adipocytes, (37) and stem cell factor, produced by Leprþ BM adipocyte precursors, is necessary for the generation of B cells and other hematopoietic cells in mice. (38) Based on these data, any impairment in adipogenesis by Sost depletion may be unrelated to the decrease in mature B cells we have observed in Sost-KO mice. Nonetheless, it would worth exploring whether Sost affects B-cell development by interfering with BM adipogenesis. Our analysis of global Sost KO mice showed significant decreases in the B-cell precursors and immature subsets, but this was not as dramatic in the Sost iCOIN/iCOIN ; Prx1-Cre mice, which suggests that there is another cell that expresses Sost that is important in supporting these early B-cell subsets. In contrast, Prx1þ and Col1þ Sost-expressing cells are critical for normal Bcell maturation. It remains to be determined whether the BM adipocytes in these Sost-deficient mice are reduced or impaired in their function to support B-cell maturation.
Our analyses demonstrate that deletion of Sost in mature osteocytes does not significantly impair B-lymphocyte development, nor does it cause the HBM observed in the global Sost À/À ; therefore, other cell types derived from Prx1-positive MSCs are critical in these processes. Furthermore, we show that Prx1-Cre deletion of Sost resulted in a significant increase in bone mass in the axial skeleton, where Sost alleles remain WT. This result suggests that Sost expressed in the vertebra is diluted out in the circulation, decreasing the net pool of Sost in the axial skeleton and contributing the increased BV/TV in this tissue; however, the vertebra-derived Sost in circulation does not act in an endocrine fashion, leaving the appendicular skeleton unperturbed. These results indicate that Sost primarily acts locally in bone via paracrine secretion and that endocrine secretion of Sost from distant sites does not significantly impair bone mass. Because anti-sclerostin antibodies are likely to become a new therapy to build bone in osteoporosis patients, it is imperative to target these therapies to bone to avoid undesired side-effects in other tissues that may require Sost for their proper function, and to test whether these therapies leave B-cell development unperturbed in these patients. Our results suggest that if Sost-depletion by Sost antibodies is limited to osteocytes, possible side effects on B-cell development and immunity could be avoided, but may elicit a more modest anabolic effect on bone mass.
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